Member Info for Bobbler

launch of Life Sciences Investment Programme brings total amount of funding available to UK’s most promising life sciences companies to £1 billion

In a further boost to the sector, British Patient Capital has recently agreed a collaboration with Abu Dhabi’s Mubadala Investment Company, one of the world’s leading sovereign investors. Under this partnership, facilitated by the Office for Investment, Mubadala has committed to invest £800 million in the UK life sciences industry and will work with British Patient Capital to identify sector trends and investment opportunities.

The missions are:
Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines

https://www.gov.uk/government/news/bold-new-life-sciences-vision-sets-path-for-uk-to-build-on-pandemic-response-and-deliver-life-changing-innovations-to-patients

SOG- don’t you be leaving boy!! We need as many stand up guys as we can muster. Yes we have a lot of oxygen thieves appearing, but we need to keep them at bay. They hate science and logical arguments, and that is their soft underbelly. How many ****ius wombelus (that’s Latin by the way) have we welcomed onboard then sent on their way? An awful lot. Stay strong brother! :-)

Silver foil: your last sentence:
“ I wouldn’t trust any of them to sit the right way round on a lavatory!!”
Fantastic! Will have me chuckling all day :-)

Stoney, good spot.
Once bitten twice shy, comes too mind. I’d like to believe mankind isn’t stupid enough to get caught with its pants down a second time.

Hi Stoney, maybe we’re all mad and seeing things that aren’t there. But there seems to be an awful lot of pointers that look very promising. Not long now.

Don’t want to listen to the LTHs, how about the guys from the Lancet?

Urgent needs to accelerate the race for COVID-19 therapeutics

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00191-7/fulltext

Extract:

In the first 100 days from a pandemic threat being identified (defined by when WHO declares a PHEIC) we should aim for the following interventions to be available, safe, effective and affordable:
Accurate and approved rapid point of care Diagnostic tests; An initial regimen of Therapeutics; and,Vaccines ready to be produced at scale for global deployment.

Apologies if this has been posted before. Would suggest UK gov is looking further ahead than the naysayers would like to believe.

diagnostics, therapeutics and vaccines (DTVs).

https://www.gov.uk/government/publications/100-days-mission-to-respond-to-future-pandemic-threats

https://www.reuters.com/business/healthcare-pharmaceuticals/eu-picks-antibody-treatments-arthritis-drug-preferred-covid-19-therapies-2021-06-29/

A first "industry matchmaking event" on therapeutics will be held on July 12-13, the Commission said on Tuesday.

*Whitty

“This winter will probably be very difficult for the NHS.” Can’t see any slow down in the hunt for therapeutics.

Guess it was anticipated the price would go higher than 7p

Stoney pinged an email to various journalists, maybe one will raise the question? Now that would be a nice end to the day.

Dated 29th June

Would appear SDC-1801 really is in the right spot.

https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299

Better link

https://www.ft.com/content/72050a34-8bab-488f-9777-1d131e583274

Good read from FT April 2021

https://www.google.co.uk/amp/s/amp.ft.com/content/72050a34-8bab-488f-9777-1d131e583274

I’m optimistic for an Agile RNS tomorrow- call me a ramper but that’s my ramp over.

A number of new posters who claim to be knowledgeable about Sar and the world in general have mentioned the issue of finance being mentioned in the latest RNS. Indeed the word was mentioned. However I’m inclined to view it from a different angle, rightly or wrongly. Abstract below:

“Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

So the first sentence makes reference to SDC-1801, “requisite approvals, and financing…etc phase 1 trials early 2022”. Then we have a full stop and a new sentence……..

“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

Clearly they are talking about 2 totally separate trials. Timing, design of trials and consultation with experts. No mention of finance, no suggestion this is subject to securing a source of funding.

Two obvious conclusions 1. If we look at Tim’s statement from 15th June RNS ref HNWI: “These new funds will also help us to further explore the potential benefit of SDC-1801 against Covid-19”
2. In my opinion the most likely, entry in the Agile program has been green lighted and they are in the process of consulting with the experts and formulating trial design.